Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1480 - Satisfaction with cancer treatments in HR + /HER2- metastatic breast cancer patients in a real world setting

Date

10 Oct 2016

Session

Poster display

Presenters

Jonathan de Courcy

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

J. de Courcy1, R. Wood1, D. Mitra2, S. Iyer2

Author affiliations

  • 1 Adelphi Real World, Adelphi Group Ltd., SK10 5JB - Bollington/GB
  • 2 Global Outcomes And Evidence, Pfizer Inc., 10017 - New York/US
More

Resources

Abstract 1480

Background

To assess patient reported cancer treatment satisfaction in HR + /HER2- metastatic breast cancer (MBC).

Methods

Physicians were recruited into the Disease Specific Program (DSP) across 5 EU countries (UK, FR, DE, ES, IT) and the US. Patients (N = 739) completed self-reported questionnaires which included the Cancer Therapy Satisfaction Questionnaire (CTSQ); this assesses 3 domains, Expectations of Therapy (ET), Feelings about Side Effects (FSE) and Satisfaction with Therapy (SWT). Each domain is scored from 0-100 with a higher score associated with the best outcome. Results are reported for the overall cohort, by current therapy and by metastatic sites. Significance was assessed using Mann-Whitney U and Kruskal-Wallis tests.

Results

A total of 611 MBC patients completed the questionnaire; mean age (SD) 66.3 (10.3). Most patients received either chemotherapy w/o endocrine therapy (46.2%) or endocrine therapy w/o chemotherapy (48.8%). 5.1% received both or neither. Mean scores (SD) for ET, FSE and SWT were 60.6 (21.0), 54.9 (17.5) and 69.4 (15.4) respectively. Domain scores are stratified by current therapy and metastatic sites in Table 1. ET scores did not vary by either stratification. Significantly worse scores were reported in the chemotherapy group for the FSE and SWT domains, while bone and visceral metastases patients reported worse FSE outcomes. When stratified by therapy, patients with bone and visceral metastases scored lower on most domains compared to other metastases groups (not significant).

CURRENT THERAPY METASTATIC SITES (± lymph nodes)
Endocrine (n = 298) Chemotherapy (n = 282) Bone not visceral (n = 195) Visceral not bone (n = 242) Bone & visceral (n = 110)
ET 61.2 (21.1) 61.4 (18.8) 62.6 (20.0) 59.2 (21.9) 57.2 (19.8)
FSE 59.7 (18.4) 50.9 (14.8)* 57.7 (17.3) 53.2 (17.2) 49.5 (15.9)*
SWT 71.6 (15.6) 68.2 (14.0)* 70.9 (14.0) 68.7 (15.7) 65.7 (16.2)

* P 

Conclusions

Therapy expectations do not differ by therapy type or metastatic sites. Patients on chemotherapy appear less satisfied with their treatment and feel worse about their side effects than patients on endocrine therapy. Presence of bone and visceral metastases is associated with worse feelings about side effects.

Clinical trial identification

Legal entity responsible for the study

Adelphi Real World

Funding

Pfizer

Disclosure

J. de Courcy, R. Wood: Adelphi Real World produces research which is funded by pharmaceutical companies. D. Mitra, S. Iyer: Employee of Pfizer, Inc. and owns Pfizer stock

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings